English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/128033
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis

AutorPastor, Marta; Moreno-Sastre, María; Esquisabel, Amaia; Sans, Eulàlia; Viñas, Miguel; Bachiller, Daniel; Asensio, Víctor José; Pozo, Ángel del; Gainza, Eusebio; Pedraz, José Luís
Palabras claveCystic fibrosis
Nanomedicine
Lipid nanoparticles
Sodium colistimethate
Pseudomonas aeruginosa
NLC
Fecha de publicación30-dic-2014
EditorElsevier
CitaciónInternational journal of pharmaceutics 477(1-2): 485-494 (2014)
Resumen© 2014 Elsevier B.V. All rights reserved. Lung impairment is the most life-threatening factor for cystic fibrosis patients. Indeed, Pseudomonas aeruginosa is the main pathogen in the pulmonary infection of these patients. In this work, we developed sodium colistimethate loaded lipid nanoparticles, namely, solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), as a strategy to enhance the antimicrobial therapy against P. aeruginosa in cystic fibrosis patients. The nanoparticles obtained displayed a 200-400 nm size, high drug entrapment (79-94%) and a sustained drug release profile. Moreover, both SLN and NLC presented antimicrobial activity against clinically isolated P. aeruginosa. The integrity of the nanoparticles was not affected by nebulization through a mesh vibrating nebulizer. Moreover, lipid nanoparticles appeared to be less toxic than free sodium colistimethate in cell culture. Finally, an in vivo distribution experiment showed that nanoparticles spread homogenously through the lung and there was no migration of lipid nanoparticles to other organs, such as liver, spleen or kidneys.
Versión del editorhttp://dx.doi.org/10.1016/j.ijpharm.2014.10.048
URIhttp://hdl.handle.net/10261/128033
DOI10.1016/j.ijpharm.2014.10.048
Identificadoresdoi: 10.1016/j.ijpharm.2014.10.048
issn: 1873-3476
Aparece en las colecciones: (IMEDEA) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.